TABLE 2.
Demographic information of participants based on the AT classification.
| Characteristic | A−T− | A−T+ | A+T− | A+T+ |
|---|---|---|---|---|
| number | 234 | 26 | 163 | 103 |
| Age, years (SD) | 69.62 (5.61) | 73.08 (5.15) | 71.61 (6.00) | 74.08 (5.78) |
| Female | 48.7% | 53.8% | 61.0% | 51.5% |
| MMSE (SD) | 29.1 (1.3) | 28.3 (2.9) | 28.2 (2.4) | 25.7 (3.4) |
| Aβ42, pg/mL (SD) | 960.9 (212.2) | 1218.9 (471.2) | 445.3 (122.9) | 419.8 (116.4) |
| Aβ42/40 ratio (SD) | 0.108 (0.015) | 0.094 (0.029) | 0.071 (0.023) | 0.046 (0.009) |
| pTau, pg/mL (SD) | 47.7 (10.9) | 102.2 (45.3) | 46.4 (16.3) | 108.3 (35.8) |
| tTau, pg/mL (SD) | 333.0 (120.2) | 696.8 (361.0) | 353.0 (153.3) | 849.8 (273.3) |
| APOE ε4 a | 20.0% | 23.1% | 48.1% | 73.0% |
| Clinical diagnosis in percentage of subgroups | ||||
| Control | 39.7% | 23.1% | 20.9% | 3.9% |
| SCD | 48.3% | 46.2% | 40.5% | 19.4% |
| MCI | 10.7% | 23.1% | 27.6% | 35.0% |
| AD | 1.3% | 7.7% | 11.0% | 41.7% |
| 100% | 100% | 100% | 100% |
Abbreviations: A+, amyloid pathology above cut‐off; Aβ, amyloid beta; AD, Alzheimer's disease; APOE ε4, apolipoprotein E ε4 allele; AT, amyloid/tau; MCI, mild cognitive impairment; MMSE, Mini‐Mental State Examination; SCD, subjective cognitive decline; SD, standard deviation; T+, tau pathology above cut‐off.
a
No APOE data were available for 17 participants.